tbuckley/cabot-search huggingface dataset:
Periodontitis is associated with hypertension: a systematic review and meta-analysis
Authors: Eva Muñoz Aguilera, Jean Suvan, Jacopo Buti, Marta Czesnikiewicz-Guzik, Aline Barbosa Ribeiro, Marco Orlandi, Tomasz J Guzik, Aroon D Hingorani, Jose Nart, Francesco D’Aiuto
Journal: Cardiovascular Research (2019)

Abstract Recent evidence suggests a link between periodontitis (PD) and hypertension, but the nature of this association remains unclear. The overall aim of this review was to critically appraise the evidence linking these two common disorders. Systematic search was conducted for studies published up to December 2018. Prevalence of hypertension in patients with PD (moderate/severe groups) vs. those without PD (non-PD) was the primary outcome. Additional outcomes included adjusted mean difference in systolic (SBP) and diastolic (DBP) blood pressure (BP) levels in PD vs. non-PD, assessment of biomarkers in PD and hypertension, and BP changes after periodontal therapy. From 81 studies selected, 40 were included in quantitative meta-analyses. Diagnoses of moderate-severe PD [odds ratio (OR) = 1.22; 95% confidence interval (CI): 1.10–1.35] and severe PD (OR = 1.49; 95% CI: 1.09–2.05) were associated with hypertension. Prospective studies confirmed PD diagnosis increased likelihood of hypertension occurrence (OR = 1.68; 95% CI: 0.85–3.35). Patients with PD exhibited higher mean SBP [weighted mean difference (WMD) of 4.49 mmHg; 95% CI: 2.88–6.11] and DBP (2.03 mmHg; 95% CI: 1.25–2.81) when compared with non-PD. Lastly, only 5 out of 12 interventional studies confirmed a reduction in BP following periodontal therapy, ranging from 3 to 12.5 mmHg of SBP and from 0 to 10 mmHg of DBP. PD is associated with increased odds of hypertension (SORT C) and higher SBP/DBP levels. The evidence suggesting that PD therapy could reduce BP is inconclusive. Although additional research is warranted on this association, these results suggest that oral health assessment and management of PD could not only improve oral/overall health and quality of life but also be of relevance in the management of patients with hypertension.
TCT-156 Patterns of Therapy Cessation in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Insights From the AVIATOR-2 International Registry
Authors: Ridhima Goel, Davide Cao, Usman Baber, Melissa Aquino, Jaya Chandrasekhar, Annapoorna Kini, Briguori Carlo, Davide Capodanno, Ioannis Iakovou, Bernhard Witzenbichler, Gennaro Sardella, Kevin Marzo, Anthony DeFranco, Alaide Chieffo, Antonio Colombo, Richard Shlofmitz, Roxana Mehran
Journal: Journal of the American College of Cardiology (2019)
Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus — Michigan Lupus Epidemiology and Surveillance Program, 2014–2015
Authors: Emily C. Somers, Jiha Lee, Afton L. Hassett, Suzanna M. Zick, Siobán D. Harlow, Charles G. Helmick, Kamil E. Barbour, Caroline Gordon, Chad M. Brummett, Deeba Minhas, Amrita Padda, Lu Wang, W. Joseph McCune, Wendy Marder
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Rheumatic diseases are a leading cause of chronic, noncancer pain. Systemic lupus erythematosus (SLE) is a chronic autoimmune rheumatic disease characterized by periodic flares that can result in irreversible target organ damage, including end-stage renal disease. Both intermittent and chronic musculoskeletal pain, as well as fibromyalgia (considered a centralized pain disorder due to dysregulation of pain processing in the central nervous system), are common in SLE. Opioids are generally not indicated for long-term management of musculoskeletal pain or centralized pain (fibromyalgia) because of lack of efficacy, safety issues ranging from adverse medical effects to overdose, and risk for addiction (1,2). In this study of 462 patients with SLE from the population-based Michigan Lupus Epidemiology and Surveillance (MILES) Cohort and 192 frequency-matched persons without SLE, nearly one third (31%) of SLE patients were using prescription opioids during the study period (2014-2015), compared with 8% of persons without SLE (p 1 year, and 31 (22%) were concomitantly on two or more opioid medications. Among SLE patients, those using the emergency department (ED) were approximately twice as likely to use prescription opioids (odds ratio [OR] = 2.1; 95% confidence interval [CI] = 1.3-3.6; p = 0.004). In SLE, the combined contributions of underlying disease and adverse effects of immunosuppressive and glucocorticoid therapies already put patients at higher risk for some known adverse effects attributed to long-term opioid use. Addressing the widespread and long-term use of opioid therapy in SLE will require strategies aimed at preventing opioid initiation, tapering and discontinuation of opioids among patients who are not achieving treatment goals of reduced pain and increased function, and consideration of nonopioid pain management strategies.
TCT-75 Infective Endocarditis After Transcatheter Aortic Valve Replacement: Findings From a UK Nationwide Linkage Study
Authors: Tom Cahill, Jonathan Raby, Paul Jewell, Adrian Banning, Jonathan Byrne, Rajesh Kharbanda, Philip Maccarthy, Martin Thornhill, Jonathan Sandoe, Peter Ludman, David Hildick-Smith, Simon Redwood, Bernard Prendergast
Journal: Journal of the American College of Cardiology (2019)
Cardiac Magnetic Resonance Stress Perfusion Imaging for Evaluation of Patients With Chest Pain
Authors: Raymond Y. Kwong, Yin Ge, Kevin Steel, Scott Bingham, Shuaib Abdullah, Kana Fujikura, Wei Wang, Ankur Pandya, Yi-Yun Chen, J. Ronald Mikolich, Sebastian Boland, Andrew E. Arai, W. Patricia Bandettini, Sujata M. Shanbhag, Amit R. Patel, Akhil Narang, Afshin Farzaneh-Far, Benjamin Romer, John F. Heitner, Jean Y. Ho, Jaspal Singh, Chetan Shenoy, Andrew Hughes, Steve W. Leung, Meera Marji, Jorge A. Gonzalez, Sandeep Mehta, Dipan J. Shah, Dany Debs, Subha V. Raman, Avirup Guha, Victor A. Ferrari, Jeanette Schulz-Menger, Rory Hachamovitch, Matthias Stuber, Orlando P. Simonetti
Journal: Journal of the American College of Cardiology (2019)

Stress cardiac magnetic resonance imaging (CMR) has demonstrated excellent diagnostic and prognostic value in single-center studies.This study sought to investigate the prognostic value of stress CMR and downstream costs from subsequent cardiac testing in a retrospective multicenter study in the United States.In this retrospective study, consecutive patients from 13 centers across 11 states who presented with a chest pain syndrome and were referred for stress CMR were followed for a target period of 4 years. The authors associated CMR findings with a primary outcome of cardiovascular death or nonfatal myocardial infarction using competing risk-adjusted regression models and downstream costs of ischemia testing using published Medicare national payment rates.In this study, 2,349 patients (63 ± 11 years of age, 47% female) were followed for a median of 5.4 years. Patients with no ischemia or late gadolinium enhancement (LGE) by CMR, observed in 1,583 patients (67%), experienced low annualized rates of primary outcome (<1%) and coronary revascularization (1% to 3%), across all years of study follow-up. In contrast, patients with ischemia+/LGE+ experienced a >4-fold higher annual primary outcome rate and a >10-fold higher rate of coronary revascularization during the first year after CMR. Patients with ischemia and LGE both negative had low average annual cost spent on ischemia testing across all years of follow-up, and this pattern was similar across the 4 practice environments of the participating centers.In a multicenter U.S. cohort with stable chest pain syndromes, stress CMR performed at experienced centers offers effective cardiac prognostication. Patients without CMR ischemia or LGE experienced a low incidence of cardiac events, little need for coronary revascularization, and low spending on subsequent ischemia testing. (Stress CMR Perfusion Imaging in the United States [SPINS]: A Society for Cardiovascular Resonance Registry Study; NCT03192891).
TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis, and a growth-promoting metabolic shift toward glycolysis in glioblastoma
Authors: Yi Fu, Dongdong Wang, Huaishan Wang, Menghua Cai, Chao Li, Xue Zhang, Hui Chen, Yu Hu, Xuan Zhang, Mingyao Ying, Wei He, Jianmin Zhang
Journal: Neuro-Oncology (2019)

The ligands of mitochondrial translocator protein (TSPO) have been widely used as diagnostic biomarkers for glioma. However, the true biological actions of TSPO in vivo and its role in glioma tumorigenesis remain elusive.
Prognostic outcome in Japanese men with prostate cancer treated with androgen-deprivation therapy (ADT) alone: Data from multi-institutional cooperative study in Kyoto Prostate Cancer Registry (KPCR)
Authors: K. Okihara, I. Takeuchi, O. Ukimura, N. Takaha, A. Kawauchi, T. Miki
Journal: Journal of Clinical Oncology (2009)

e16106 Background: There is scarce data of ADT alone concerning prognostic outcome in terms of clinical stage, and in comparison with radical treatments specifically in men without metastatic diseases. The aim of this study was to analyze prognostic outcome for ADT alone, and to assess the significant prognostic parameters in Japanese men. Methods: Database in the KPCR, which is a multi-institutional urologic cancer registry, was screened to identify prostate cancer patients who received ADT alone between 1988 and 2008. Clinical data including age, clinical stage, biopsy differentiation, initial prostate-specific antigen (PSA) level and type of ADT: luteinizing hormone-releasing hormone (LH-RH) monotherapy or combined androgen blockade (CAB), were analyzed. Time to prostate cancer relapse as well as cause specific survivals were also analyzed. Results: Of 1167 men with prostate cancer registered in KPCR, 373 patients (32%) received primary ADT and continued ADT alone during the observation period. Of those men, age and PSA level ranged from 52 to 95 y.o (median: 75) and from 2.17 to 8,650 ng/ml (median: 23.5), respectively. The numbers of clinical stage in A to B, C and D were 148 (40%), 127 (34%), and 98 (26%), respectively. The observation period ranged from 1 to 125 months (median: 55). Of the 373 men, 113 men (30%) recurred after the primary ADT. Of the 131men, 36 men (10%) changed from LH-RH monotherapy to CAB, and 46 (12%) and 52 men (14%) underwent anti-androgen alternative therapy and secondary hormonal therapy using estramustine phosphate and/or oral dexamethasone, respectively. There was a significant difference in 5-year cause specific survival between stage A-C (98%) and D (63%, p &lt; 0.0001). Cox proportional hazards multivariate regression analyses revealed that localized cancer (stage A and B) was the most significant prognostic factor in the time to relapse (p &lt; 0.0001) as well as the cause specific survival (p &lt; 0.0001). Conclusions: There was substantial number of men with localized disease who were treated ADT alone. The use of ADT therapy alone appeared to have favor prognosis in the majority of patients without metastatic diseases, at least for an intermediate period. No significant financial relationships to disclose.
TCT-413 Different Safety Pattern of Ticagrelor Monotherapy Following Percutaneous Coronary Interventions Related to Pulse Pressure Levels: A Subanalysis of the GLOBAL LEADERS Randomized Multicenter Trial
Authors: Ana Paula de Faria, Rodrigo Modolo, Ply Chichareon, Chun-Chin Chang, Norihiro Kogame, Mariusz Tomaniak, Joanna Wykrzykowska, Robert de Winter, Christian Hamm, Peter Juni, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Yoshinobu Onuma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2019)
The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing
Authors: Matthew S. GoodSmith, M. Reza Skandari, Elbert S. Huang, Rochelle N. Naylor
Journal: Diabetes Care (2019)

OBJECTIVE In the U.S., genetic testing for maturity-onset diabetes of the young (MODY) is frequently delayed because of difficulty with insurance coverage. Understanding the economic implications of clinical genetic testing is imperative to advance precision medicine for diabetes. The objective of this article is to assess the cost-effectiveness of genetic testing, preceded by biomarker screening and followed by cascade genetic testing of first-degree relatives, for subtypes of MODY in U.S. pediatric patients with diabetes. RESEARCH DESIGN AND METHODS We used simulation models of distinct forms of diabetes to forecast the clinical and economic consequences of a systematic genetic testing strategy compared with usual care over a 30-year time horizon. In the genetic testing arm, patients with MODY received treatment changes (sulfonylureas for HNF1A- and HNF4A-MODY associated with a 1.0% reduction in HbA1c; no treatment for GCK-MODY). Study outcomes included costs, life expectancy (LE), and quality-adjusted life years (QALY). RESULTS The strategy of biomarker screening and genetic testing was cost-saving as it increased average quality of life (+0.0052 QALY) and decreased costs (−$191) per simulated patient relative to the control arm. Adding cascade genetic testing increased quality-of-life benefits (+0.0081 QALY) and lowered costs further (−$735). CONCLUSIONS A combined strategy of biomarker screening and genetic testing for MODY in the U.S. pediatric diabetes population is cost-saving compared with usual care, and the addition of cascade genetic testing accentuates the strategy’s benefits. Widespread implementation of this strategy could improve the lives of patients with MODY while saving the health system money, illustrating the potential population health benefits of personalized medicine.
TCT-462 Valvular Remodeling and Myocyte Dysfunction at an Early Stage of Ischemic Mitral Regurgitation in a Relevant Translational Pig Model
Authors: Ouafa Hamza, Attila Kiss, Beata Bodi, Zoltan Papp, Anne Kramer, Katharina Tillmann, Bruno Podesser
Journal: Journal of the American College of Cardiology (2019)
Adult Strabismus Preferred Practice Pattern®
Authors: Linda R. Dagi, Federico G. Velez, Steven M. Archer, Hatice Tuba Atalay, Brian N. Campolattaro, Jonathan M. Holmes, Natalie C. Kerr, Burton J. Kushner, Sarah E. Mackinnon, Evelyn A. Paysse, Matthew Simon Pihlblad, Stacy L. Pineles, Mitchell B. Strominger, David R. Stager, David Stager, Hilda Capo
Journal: Ophthalmology (2019)
TCT-428 Altered Valve Eccentricity and Hemodynamics in Sievers Type 0 Compared With Type 1 Bicuspid Aortic Valves Post Transcatheter Aortic Valve Replacement
Authors: Scott Chadderdon, Reyhaneh Akhavein, Sam McNeily, Howard Song, Cristina Fuss, Firas Zahr
Journal: Journal of the American College of Cardiology (2019)
TCT-489 Base Camp to Mount Everest: Milestones in Advancing a Single-Lead for STEMI Detection
Authors: Sameer Mehta, Francisco Fernandez, Carlos Villagran, Sebastian Niklitschek, Felipe Vera, Alejandra Frauenfelder, Mariana Ceschim, Daniel Vieira, Jorge Mazzini, Anibal Munguia, Maria Acosta, Benjamin Wood, Juhee Lee
Journal: Journal of the American College of Cardiology (2019)
A neuroscientific approach to increase gender equality
Authors: Christiane Schreiweis, Emmanuelle Volle, Alexandra Durr, Alexandra Auffret, Cécile Delarasse, Nathalie George, Magali Dumont, Bassem A. Hassan, Nicolas Renier, Charlotte Rosso, Michel Thiebaut de Schotten, Eric Burguière, Violetta Zujovic
Journal: Nature Human Behaviour (2019)
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Authors: Johannes Hofland, Gregory Kaltsas, Wouter W de Herder
Journal: Endocrine Reviews (2019)

Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary and gastrointestinal tracts. The majority of these neoplasms have a well-differentiated grade and are termed neuroendocrine tumors (NETs). This subgroup is characterized by limited proliferation and patients affected by these tumors carry a good to moderate prognosis. A substantial subset of patients presenting with a NET suffer from the consequences of endocrine syndromes as a result of the excessive secretion of amines or peptide hormones, which can impair their quality of life and prognosis. Over the past 15 years, critical developments in tumor grading, diagnostic biomarkers, radionuclide imaging, randomized controlled drug trials, evidence-based guidelines, and superior prognostic outcomes have substantially altered the field of NET care. Here, we review the relevant advances to clinical practice that have significantly upgraded our approach to NET patients, both in diagnostic and in therapeutic options.
TCT-446 Sex Related Differences in In-Hospital Outcomes of Transcatheter Mitral Valve Repair: Perspectives From a National Database
Authors: Ayman Elbadawi, Islam Elgendy, Omar Al-Taweel, Ahmed Mohamed, Karim Mahmoud, Mohamed Omer, Gbolahan Ogunbayo, Mohamed Hamed, Odunayo Olorunfemi, Syed Gilani, Paul Kumfa, Wissam Khalife, Umamahesh Rangasetty
Journal: Journal of the American College of Cardiology (2019)
TCT-17 Coronary Obstruction Risk Assessment: A Comparison of Snorkel Stenting and BASILICA
Authors: John Lisko, Norihiko Kamioka, Vasilis Babaliaros, Shinichi Shirai, Tomohiro Kawaguchi, Masanori Yamamoto, Masaki Miyasaka, Jaffar Khan, Samuel Maidman, Patrick Gleason, Lucia Alvarez, Isida Byku, Kendra Grubb, Robert Guyton, Toby Rogers, Robert Lederman, Adam Greenbaum
Journal: Journal of the American College of Cardiology (2019)
The Affordable Care Act and Health Insurance Coverage Among People With Diagnosed and Undiagnosed Diabetes: Data From the National Health and Nutrition Examination Survey
Authors: Rebecca Myerson, John Romley, Tommy Chiou, Anne L. Peters, Dana Goldman
Journal: Diabetes Care (2019)

Despite recent improvements, many people with diabetes remain undiagnosed, and those who are diagnosed often fail to reach their targets (1,2). Insurance coverage can change the health trajectory of people with diabetes by facilitating timely diabetes diagnosis and management (3,4). It is therefore important to understand how public policies can increase coverage among people with diabetes.

Increasing access to health insurance was a key goal of the Patient Protection and Affordable Care Act (ACA), but gaps remain in our knowledge about coverage gains among people with diabetes. An analysis of data from 2009 to 2016 found that insurance coverage for adults with diagnosed diabetes increased after key ACA provisions were implemented (5). However, the study did not include people whose diabetes is undiagnosed—a group comprising approximately one-third of all adults with diabetes prior to the ACA, including many people who are underserved minorities (1). To address this gap, we used the National Health and Nutrition Examination Survey (NHANES) to estimate the full changes in insurance coverage under the ACA for adults with diabetes, including undiagnosed diabetes.

We analyzed data from the 2005–2016 waves of NHANES, a repeated cross-sectional survey with biomarkers that is nationally representative of the noninstitutionalized civilian population on a biennial basis. Our sample included 2,401 nonpregnant U.S. citizens aged 26–64 years with diabetes, defined as HbA …
Catalase‐Functionalized Iron Oxide Nanoparticles Reverse Hypoxia‐Induced Chemotherapeutic Resistance
Authors: Tin‐Yo Yen, Zachary R. Stephen, Guanyou Lin, Qingxin Mu, Mike Jeon, Stela Untoro, Parker Welsh, Miqin Zhang
Journal: Advanced Healthcare Materials (2019)

Abstract Intratumoral hypoxia is a major contributor to multiple drug resistance (MDR) in cancer, and can lead to poor prognosis of patients receiving chemotherapy. Development of an MDR‐inhibitor that mitigates the hypoxic environment is crucial for cancer management and treatment. Reported is a biocompatible and biodegradable catalase‐conjugated iron oxide nanoparticle (Cat‐IONP) capable of converting reactive oxygen species to molecular oxygen to supply an oxygen source for the hypoxic tumor microenvironment. Cat‐IONP demonstrates initial enzymatic activity comparable to free catalase while providing a nearly threefold increase in long‐term enzymatic activity. It is demonstrated that Cat‐IONP significantly reduces the in vitro expression of hypoxia‐inducible factors at the transcription level in a breast cancer cell line. Co‐treatment of Cat‐IONP and paclitaxel (PTX) significantly increases the drug sensitivity of hypoxic‐cultured cells, demonstrating greater than twofold and fivefold reduction in cell viability in comparison to cells treated only with 80 and 120 × 10 −6 m PTX, respectively. These findings demonstrate the ability of Cat‐IONP to act as an MDR‐inhibitor at different biological levels, suggesting a promising strategy to combat cancer‐MDR and to optimize cancer management and treatment outcomes.
TCT-118 Balloon Pulmonary Angioplasty for Segmental and Subsegmental Thromboembolic Lesions in Patients With Chronic Thromboembolic Pulmonary Hypertension
Authors: Leo Bockeria, Karen Petrosyan, Andrey Sobolev, Issa Jeblawi, Vladimir Losev, Dadabaev Gulamjan, Sergey Gorbachevskiy
Journal: Journal of the American College of Cardiology (2019)
Severe primary cutaneous Cryptococcus gattii causing ulcerative cellulitis in an immunocompetent patient
Authors: Glorijoy Shi En Tan, Ravinder Singh, Tricia Yi Rui Chong, Pei Qi Su, Joyce Siong See Lee, Kevin Jian Hao Wong, Justina Wei Lynn Tan, Shawn Vasoo
Journal: The Lancet Infectious Diseases (2019)
Elevated pretreatment serum biomarkers and correlation with progression-free (PFS) and overall survival (OS) in first-line trastuzumab-treated metastatic breast cancer.
Authors: Suhail M. Ali, Kim Leitzel, Uchechi Anyanwu, Hui Ying Hou, Matthew Stephen Evans, Vikas Shrivastava, Wolfgang Köstler, Eva-Maria Fuchs, Francisco J. Esteva, Walter P. Carney, Allan Lipton
Journal: Journal of Clinical Oncology (2013)

622 Background: Approximately one-half of HER2-positive breast cancer patients will respond tofirst-line trastuzumab-containing therapy. However, in those patients with an initial trastuzumab response, most will progress within a year with acquired resistance. Since trastuzumab treatment is also now used in the HER2-positive adjuvant breast cancer setting, trastuzumab resistance will continue to be a recurring clinical problem, and better predictive and prognostic biomarkers are urgently needed. Methods: Seven serum biomarkers (carbonic anhydrase 9 (CA9), endoglin, HER2, IGF-1R, tissue inhibitor of metalloproteinase-1 (TIMP-1), urokinase-type plasminogen activator (uPA), and VEGF-A (isoform 165) were measured using ELISA assays in 81 metastatic breast cancer patients before starting first-line trastuzumab-containing therapy. The endoglin and IGF-IR ELISAs were from R&amp;D Systems; others were from WILEX/Oncogene Science, Cambridge, MA. PFS and OS were analyzed using the Kaplan-Meier method and Cox modeling with continuous pretreatment serum biomarker variables. Results: For univariate PFS analysis, higher pretreatment serum biomarkers (except IGF-1R and VEGF-A) predicted reduced PFS (p&lt;0.05) to first-line trastuzumab-containing therapy. In multivariate PFS analysis, only serum CA9 (p= 0.038) remained a significant independent covariate. In univariate OS analysis, higher pretreatment serum biomarkers (except IGF-1R and VEGF-A) were prognostic for reduced OS (p&lt;0.05). In multivariate analysis for OS, TIMP-1 (p=0.001) and CA9 (p=0.04) remained significant independent prognostic factors, as well as line of chemotherapy (3 vs. 2 or 1 line)(p=0.005), and hormone receptor status (ER and/or PR positive vs. negative)(p=0.013). Conclusions: Higher pretreatment serum CA9 (a marker of hypoxia) predicted reduced PFS, and higher serum CA9 and TIMP-1 predicted reduced OS in metastatic breast cancer patients treated with first-line trastuzumab-containing therapy. These serum biomarkers deserve further study in larger trials of HER2-targeted breast cancer treatment. Supported by a grant from Komen for the Cure.